Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression

It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) should be selected for patients with advanced non–small‐cell lung cancer (NSCLC) exhibiting high PD‐L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicente...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikezawa, Yasuyuki, Mizugaki, Hidenori, Morita, Ryo, Tateishi, Kazunari, Yokoo, Keiki, Sumi, Toshiyuki, Kikuchi, Hajime, Kitamura, Yasuo, Nakamura, Atsushi, Kobayashi, Maki, Aso, Mari, Kimura, Nozomu, Yoshiike, Fumiaki, Furuta, Megumi, Tanaka, Hisashi, Sekikawa, Motoki, Hachiya, Tsutomu, Nakamura, Keiichi, Shimokawa, Mototsugu, Oizumi, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207363/
https://www.ncbi.nlm.nih.gov/pubmed/35377496
http://dx.doi.org/10.1111/cas.15361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207363/
https://www.ncbi.nlm.nih.gov/pubmed/35377496
http://dx.doi.org/10.1111/cas.15361

Ejemplares similares